Valuation: Alector, Inc.

Market Cap 168M 147M 137M 126M 237M 16.08B 240M 1.63B 637M 7.94B 629M 616M 27.44B P/E 2026 *
-1.76x
P/E 2027 * -2.35x
Enterprise Value -79.49M -69.88M -65.05M -59.74M -112M -7.62B -114M -773M -302M -3.76B -298M -292M -13.01B EV / Sales 2026 *
-11.6x
EV / Sales 2027 * -6.94x
Free-Float
86.82%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Alector, Inc.

1 day-0.33%
1 week-0.97%
Current month-24.13%
1 month-26.68%
3 months-36.19%
6 months-20.16%
Current year-2.24%
1 week 1.46
Extreme 1.455
1.58
1 month 1.37
Extreme 1.37
2.14
Current year 1.37
Extreme 1.37
2.74
1 year 1.09
Extreme 1.09
3.4
3 years 0.87
Extreme 0.87
9.06
5 years 0.87
Extreme 0.87
31.24
10 years 0.87
Extreme 0.87
43.32
Manager TitleAgeSince
Chief Executive Officer 71 01/05/2013
Director of Finance/CFO 52 20/06/2025
Chief Tech/Sci/R&D Officer - 01/01/2017
Director TitleAgeSince
Director/Board Member 71 01/05/2013
Director/Board Member 72 01/10/2018
Chairman 77 13/06/2023
Date Insider Type Main position Quantity % Market Cap.
9/7/26 Free

Controller/Auditor

20,000 0.0180%
17/6/26 Free

Director

38,150 0.0344%
17/6/26 Free

Director

38,150 0.0344%
Change 5-day change 1-year change 3-year change Capi.($)
-0.33%-0.97%-13.35%-76.06% 168M
-1.82%+2.24%+51.86%+71.19% 56.19B
-0.27%+0.35%+40.26%+79.88% 54.83B
+0.29%-0.08%-18.20%-14.11% 23.04B
-1.03%-3.65%+2.85%+390.16% 22.7B
-0.21%-0.62%+20.56%-10.90% 20.23B
0.00%+3.91%+28.55%-28.89% 17.83B
-0.97%-0.59%+33.12%+550.67% 15.65B
+5.29%+1.70%+185.09%+333.94% 15.24B
-0.24%+0.44%+26.98%+183.95% 14.03B
Average +0.10%+1.35%+35.77%+147.98% 23.99B
Weighted average by Cap. -0.26%+1.08%+39.21%+135.27%

Financials

2026 *2027 *
Net sales 6.86M 6.03M 5.61M 5.15M 9.68M 658M 9.8M 66.7M 26.05M 325M 25.74M 25.19M 1.12B 22.88M 20.12M 18.72M 17.2M 32.29M 2.19B 32.72M 223M 86.93M 1.08B 85.89M 84.04M 3.74B
Net income -94.11M -82.73M -77.01M -70.73M -133M -9.03B -135M -915M -358M -4.46B -353M -346M -15.4B -96.62M -84.93M -79.06M -72.61M -136M -9.27B -138M -940M -367M -4.58B -363M -355M -15.81B
Net Debt -247M -217M -202M -186M -349M -23.7B -353M -2.4B -939M -11.7B -928M -908M -40.45B -326M -287M -267M -245M -461M -31.3B -467M -3.17B -1.24B -15.45B -1.23B -1.2B -53.42B
Logo Alector, Inc.
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Employees
103
Date Price Change Volume
28/07/26 USD 1.520 +0.66% 15,979
27/07/26 USD 1.510 +2.03% 229,001
24/07/26 USD 1.480 -0.67% 325,295
23/07/26 USD 1.490 -2.61% 607,111
22/07/26 USD 1.530 -0.65% 333,441
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
1.510USD
Average target price
3.100USD
Spread / Average Target
+105.30%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALEC Stock